Bristol Myers Squibb (BMY) EPS (Basic) (2009 - 2026)

Bristol Myers Squibb (BMY) has reported EPS (Basic) for 18 consecutive years, with $1.62 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 151.69% year-over-year to $1.62 in Q2 2026; TTM through Jun 2026 was $4.54, a 82.48% increase from a year earlier, with the FY2025 full-year figure at $3.47, up 178.72% from the prior year.
• EPS (Basic) was $1.62 for Q2 2026 at Bristol Myers Squibb, up from $1.31 in the prior quarter.
• Over five years, EPS (Basic) peaked at $1.62 in Q2 2026 and troughed at -$5.89 in Q1 2024.
• A 5-year average of $0.49 and a median of $0.84 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) tumbled 645.01% in 2024 and soared 1324.03% in 2025, its largest moves.
• Over 5 years, EPS (Basic) stood at $0.95 in 2022, then decreased by 10.42% to $0.85 in 2023, then sank by 95.6% to $0.04 in 2024, then jumped by 1324.03% to $0.53 in 2025, then jumped by 204.14% to $1.62 in 2026.
• The last three EPS (Basic) figures came in at $1.62 (Q2 2026), $1.31 (Q1 2026), and $0.53 (Q4 2025), per Business Quant data.